
Verrica Pharmaceuticals Inc.: updates and filings
Price
$2.93
November 20, 2026Market cap $50M
What Ploutos Investor adds for Verrica Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 9, 2026Officer or director change, shareholder voteForm8-K
- May 12, 2026Shares registered for employeesFormS-8
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- Apr 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 20, 2026Additional annual meeting materialFormDEFA14A
- Apr 20, 2026Annual meeting proxy statementFormDEF 14A
- Mar 11, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 11, 2026Results of operationsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Dec 30, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Dec 30, 2025Officer or director changeForm8-K
- Dec 23, 2025FilingFormEFFECT
- Dec 19, 2025Correspondence with the SECFormCORRESP
- Dec 15, 2025Shelf registration for future offeringsFormS-3
- Dec 10, 2025FilingFormD
- Dec 3, 2025Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 28, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 9, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 12, 2026 | S-8 | Shares registered for employees | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| Apr 20, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 20, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 11, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 11, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Dec 30, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Dec 30, 2025 | 8-K | Officer or director change | Document |
| Dec 23, 2025 | EFFECT | Filing | Document |
| Dec 19, 2025 | CORRESP | Correspondence with the SEC | Document |
| Dec 15, 2025 | S-3 | Shelf registration for future offerings | Document |
| Dec 10, 2025 | D | Filing | Document |
| Dec 3, 2025 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 28, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 17, 2015.
The full analysis
What do Verrica Pharmaceuticals's filings show?
The filings are where every one of Verrica Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.